Maxim Group analyst Jason McCarthy weighed in today with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the company made amendments on its …
In research report issued today, J.P.
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced that data from 11 abstracts (two oral presentations, six poster presentations and …
J.P.
Canaccord Genuity analyst John Newman was out pounding the table on Celgene Corporation (NASDAQ:CELG) Thursday, reiterating a Buy rating and price target of $156, which …
Celgene Corporation (NASDAQ:CELG) announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients …
In a research report issued Friday, Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of …
In a research report issued today, Cantor analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of …
Celgene Corporation (NASDAQ:CELG) and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, announced a definitive share purchase agreement …
